Health Canada has conditionally greenlit the use of lecanemab, a drug aimed at slowing down the progression of early-stage Alzheimer’s disease, sparking discussions surrounding its efficacy and accessibility in Canada. Lecanemab, an artificially synthesized antibody administered through intravenous infusion, targets the accumulation of amyloid plaque in the brain, a key characteristic of Alzheimer’s disease.
Although lecanemab is not a cure and cannot reverse the disease or restore lost memories, it marks a significant milestone as the first disease-modifying treatment for Alzheimer’s approved for use in Canada. Unlike current medications that mainly alleviate symptoms, lecanemab has the potential to alter the disease’s course.
The approval has prompted considerations on the drug’s effectiveness and its potential impact on Canada’s healthcare system for individuals affected by Alzheimer’s, their families, healthcare providers, and government bodies.
Eligibility for lecanemab, also known as Leqembi, is for individuals with mild cognitive impairment and early stages of Alzheimer’s disease. To qualify, patients must have documented amyloid plaque presence in the brain, as per the drug manufacturer’s requirements. Additionally, individuals need to undergo genetic testing for variants linked to adverse effects, with the treatment limited to those with one or no copies of the APOE4 gene variant to reduce the risk of brain swelling or bleeding.
Access to the necessary genetic testing varies across Canadian provinces and territories, posing a potential challenge for some patients seeking treatment. While lecanemab offers promise in slowing down disease progression, its benefits and cost, approximately $26,000 US annually in other countries, raise questions about its overall value and practicality for widespread prescription.
Ongoing monitoring through specialized diagnostics, such as PET scans or MRIs, is essential for individuals receiving lecanemab to ensure safety and effectiveness. The Alzheimer’s Society emphasizes the need for substantial investments in resources, infrastructure, training, and healthcare pathways to deliver such treatments effectively and equitably.
Side effects, including brain swelling or bleeding, have been reported in clinical trials of lecanemab and similar antibody treatments, underscoring the importance of understanding who will benefit most from the medication. The variability in treatment response among different subgroups, such as gender and age, highlights the need for further research to optimize its use.
The Alzheimer’s Society advocates for swift market introduction and public funding of lecanemab in Canada to ensure affordable access for all eligible patients. While regulatory approval is a crucial step, it may take up to two years for new medications to be publicly covered, with private or extended benefits offering earlier access options. In contrast, Britain’s National Institute for Health and Care Excellence (NICE) concluded that the benefits of lecanemab may not justify the costs to the publicly funded healthcare system, including medication provision and side-effect monitoring.
Overall, the conditional approval of lecanemab represents a significant advancement in Alzheimer’s treatment, raising hopes for disease modification and improved outcomes for individuals affected by this debilitating condition.